ストックスクリーナーアプリを入手
4.57
2.97%
-0.14
前日終値:
$4.71
開ける：
$4.66
24時間の取引高:
39,595
Relative Volume:
0.38
時価総額：
$14.68M
収益：
-
当期純損益:
$-37.68M
株価収益率:
-0.3861
EPS:
-11.8364
ネットキャッシュフロー:
$-30.65M
1週間 パフォーマンス:
-2.35%
1か月 パフォーマンス:
-10.92%
6か月 パフォーマンス:
-76.98%
1年 パフォーマンス:
+1,050%
1日の値動き範囲:
$4.415
$4.66
1週間の範囲:
$4.415
$5.06
52週間の値動き範囲:
$0.40
$20.00
Passage Bio Inc Stock (PASG) Company Profile
名前
Passage Bio Inc
セクター
電話
(267) 866-0312
住所
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.57 | 14.68M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-04-21 | ダウングレード | Wedbush | Outperform → Neutral |
| 2026-03-31 | 開始されました | Oppenheimer | Outperform |
| 2026-02-10 | 再開されました | Chardan Capital Markets | Buy |
| 2024-11-29 | 再開されました | Wedbush | Outperform |
| 2024-09-03 | 開始されました | Rodman & Renshaw | Buy |
| 2022-03-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-19 | ダウングレード | Goldman | Buy → Neutral |
| 2021-07-01 | 開始されました | Raymond James | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-03-04 | アップグレード | Goldman | Neutral → Buy |
| 2021-02-04 | 開始されました | Guggenheim | Buy |
| 2021-01-25 | 開始されました | Wedbush | Outperform |
| 2021-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 開始されました | Citigroup | Neutral |
| 2020-08-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-25 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2020-03-24 | 開始されました | Cowen | Outperform |
| 2020-03-24 | 開始されました | Goldman | Buy |
| 2020-03-24 | 開始されました | JP Morgan | Overweight |
すべてを表示
Passage Bio Inc (PASG) 最新ニュース
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits
Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline - ad-hoc-news.de
Layoff Tracker: Novartis cuts New Jersey workforce again, ousting 322 employees - BioSpace
Passage Bio focuses on genetic medicine strategy as investors weigh long-term potential - ad-hoc-news.de
SPRY, PASG, BOXL: Why these stocks plunged double digits in after-hours trading today - MSN
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc - GuruFocus
Passage Bio, Inc. Financial Disclosures & SEC Filings - TradingView
Passage Bio explores gene therapy potential as investors weigh long-term prospects - ad-hoc-news.de
Deal Watch: Boehringer Ingelheim Unveils Cancer Pacts With Immunai And Combotope - insights.citeline.com
Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake - TradingView
Passage BIO (NASDAQ: PASG) holder Lynx1 reports 21% ownership amid Remix deal - Stock Titan
Passage Bio (PASG) Slides 6% as Shares Test Key Support Near $4.35AD Line Divergence - dars.gov.et
PASGPassage Bio Inc Latest SEC Filings - Finviz
Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio - Legal Desire Media and Insights
Passage Bio (PASG) holder adds 50,055 shares in open-market buy - Stock Titan
Passage Bio to Merge With Remix in Deal Backed by $100 Million Financing - MyChesCo
PASG Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 8.55%Earnings Revision Report - dars.gov.et
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired - RTTNews
Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG) - TradingView
Enterprise value to EBIT forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to sales forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to book forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to earnings forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Enterprise value to EBITDA forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Enterprise value to revenue forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Passage Bio, Inc. Actuals & Estimates (BOATS:PASG) - TradingView
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
Remix Therapeutics secures $100M and a reverse merger - The Business Journals
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Remix to go public in reverse merger with once high-flying Passage Bio - BioPharma Dive
PASG Forecast — Price Target — Prediction for 2027 - TradingView
Which stocks are moving before the opening bell on Thursday? - ChartMill
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Remix to enter Nasdaq through Passage Bio reverse merger - The Pharma Letter
Passage Bio and Remix Therapeutics Announce Merger to Advance RNA-Targeted Cancer Therapies with $100M Financing – Minichart - Minichart
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - TradingView
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
Stocks to Watch: Micron, ARS Pharmaceuticals, MillerKnoll, Passage Bio - Moomoo
Passage Bio Shares Slide on Merger With Remix Therapeutics - Moomoo
Passage Bio And Remix Therapeutics Announce Merger Agreement - TradingView
Passage Bio (PASG) Slides 3.9% as Momentum Falters Near Key SupportWave Truncation - dars.gov.et
Spurned by the FDA, Passage Bio finds an exit through Remix - Fierce Biotech
Passage Bio (PASG) to merge with Remix; Remix private placement tops $100M - Stock Titan
Passage Bio to merge with Remix Therapeutics in all-stock deal - Investing.com
9 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView
Passage Bio and Remix Therapeutics Announce Merger Agreement - The Manila Times
Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise - Stock Titan
Passage Bio | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsmoomoo - Moomoo
Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan
PASG Stock Slumps 16% After-HoursWhat's Driving The Selloff? - Mena FN
Passage Bio Inc (PASG) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):